Department of Ophthalmology, Duke University, Durham, NC 27710, USA.
Department of Medicine, Duke University, Durham, NC 27710, USA.
Hum Mol Genet. 2023 Oct 17;32(21):3053-3062. doi: 10.1093/hmg/ddad128.
Pseudoexfoliation glaucoma (PEXG) is characterized by dysregulated extracellular matrix (ECM) homeostasis that disrupts conventional outflow function and increases intraocular pressure (IOP). Prolonged IOP elevation results in optic nerve head damage and vision loss. Uniquely, PEXG is a form of open angle glaucoma that has variable penetrance, is difficult to treat and does not respond well to common IOP-lowering pharmaceuticals. Therefore, understanding modulators of disease severity will aid in targeted therapies for PEXG. Genome-wide association studies have identified polymorphisms in the long non-coding RNA lysyl oxidase-like 1-antisense 1 (LOXL1-AS1) as a risk factor for PEXG. Risk alleles, oxidative stress and mechanical stretch all alter LOXL1-AS1 expression. As a long non-coding RNA, LOXL1-AS1 binds hnRNPL and regulates global gene expression. In this study, we focus on the role of LOXL1-AS1 in the ocular cells (trabecular meshwork and Schlemm's canal) that regulate IOP. We show that selective knockdown of LOXL1-AS1 leads to cell-type-specific changes in gene expression, ECM homeostasis, signaling and morphology. These results implicate LOXL1-AS1 as a modulator of cellular homeostasis, altering cell contractility and ECM turnover, both of which are well-known contributors to PEXG. These findings support LOXL1-AS1 as a key target for modifying the disease.
假性剥脱性青光眼(PEXG)的特征是细胞外基质(ECM)稳态失调,破坏常规流出功能并增加眼内压(IOP)。IOP 升高持续时间长会导致视神经头损伤和视力丧失。独特的是,PEXG 是一种开角型青光眼,具有可变的外显率,难以治疗,对常见的降眼压药物反应不佳。因此,了解疾病严重程度的调节剂将有助于针对 PEXG 的靶向治疗。全基因组关联研究已经确定了赖氨酸氧化酶样 1 反义 1(LOXL1-AS1)长非编码 RNA 中的多态性是 PEXG 的一个风险因素。风险等位基因、氧化应激和机械拉伸都会改变 LOXL1-AS1 的表达。作为一种长非编码 RNA,LOXL1-AS1 与 hnRNPL 结合并调节全局基因表达。在这项研究中,我们专注于 LOXL1-AS1 在调节 IOP 的眼部细胞(小梁网和施莱姆氏管)中的作用。我们表明,LOXL1-AS1 的选择性敲低导致基因表达、ECM 稳态、信号和形态的细胞类型特异性变化。这些结果表明 LOXL1-AS1 是细胞稳态的调节剂,改变细胞收缩性和 ECM 周转率,这两者都是 PEXG 的已知贡献者。这些发现支持 LOXL1-AS1 作为修饰疾病的关键靶点。